Drug
ProMune clinical trials
Also written CPG 7909, PF-3512676 and agatolimod sodium.
- studies test it
- 24
- open now
- 0
- in phase 3
- 2
- first study started
- 2001
How studies write it
Studies that test it under each name
Development codes
- CPG 7909
- 11
Other names
Studies by the year they started
24 studies that test it; most in 2004 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 17
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 12
Pfizer (12) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Ronald Levy (2) · Ahmad Tarhini (1) · University of Iowa (1) · Mayo Clinic (1) · City of Hope Medical Center (1) · University of Aarhus (1)
Often tested with
Tested in the same studies.
Trastuzumab (2) · Paclitaxel (2) · Carboplatin (2) · Protein Subunit Vaccines (1) · Rituximab (1) · Erlotinib (1) · Pneumococcal Vaccines (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses ProMune is read from its arms, and is right about nine times in ten.
Testing it · 24
- Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedPhase 1Ahmad TarhiniNCT00471471Written as PF3512676
- A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell LymphomasCompletedPhase 2Ronald LevyNCT00880581Written as PF-3512676
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously TreatedCompletedPhase 1University of IowaNCT00233506Written as CpG 7909
- Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.WithdrawnPhase 1/2Stanford UniversityNCT00226993Written as CPG 7909
- Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaCompletedPhase 1/2Mayo ClinicNCT00438880Written as Agatolimod Sodium
- Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast CancerTerminatedPhase 2Bhuvaneswari RamaswamyNCT00824733Written as PF03512676
- A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.WithdrawnPhase 2PfizerNCT00471159Written as PF-3512676
- Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung CancerTerminatedPhase 3PfizerNCT00254891Written as PF-3512676 + Paclitaxel + Carboplatin
- Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLCTerminatedPhase 3PfizerNCT00254904Written as PF-3512676
- CPG 7909 + Local Radiotherapy in Recurrent Low-Grade LymphomasCompletedPhase 1/2Ronald LevyNCT00185965Written as CPG 7909
- Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 AdjuvantTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01164514Written as CPG 7909
- Vaccine Therapy in Preventing Cytomegalovirus in Healthy ParticipantsCompletedPhase 1City of Hope Medical CenterNCT00722839Written as agatolimod sodium
- Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast CancerCompletedPhase 1/2PfizerNCT00031278Written as CPG 7909
- Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung CancerCompletedPhase 2PfizerNCT00321815Written as PF-3512676 + Erlotinib
- Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLCTerminatedPhase 2PfizerNCT00313768Written as carboplatin + paclitaxel + bevacizumab + PF-3512676
- Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung CancerTerminatedPhase 2PfizerNCT00321308Written as pemetrexed + PF-3512676
- PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)CompletedPhase 2PfizerNCT00043368Written as PF-3512676
- CPG 7909 in Patients With Cutaneous T-Cell LymphomaCompletedPhase 1/2PfizerNCT00043420Written as PF-3512676
- CPG 7909 in Patients Wih Stage IV Renal Cell CancerCompletedPhase 1/2PfizerNCT00043407Written as CPG 7909
- CPG 7909 Injection in Non-Small Cell Lung CancerCompletedPhase 2PfizerNCT00070629Written as CPG 7909
See all 24 studies that test ProMune →
Given in every arm · 4 — ProMune is usual care beside what is tested
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07221162Written as CpG 7909
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCLCompletedPhase 2Ronald LevyNCT00490529Written as PF-3512676
- Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedPhase 2University of Southern CaliforniaNCT00085189Written as agatolimod sodium
- AMA1-C1/Alhydrogel + CpG 7909 for MalariaCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00344539Written as CPG 7909 Oligodeoxynucleotide (VaxImmune®)